MeiraGTx Holdings shares surge 11.48% intraday after FDA breakthrough designation for gene therapy and better-than-expected revenue.

MeiraGTx Holdings surged 11.48% in intraday trading, driven by the FDA granting breakthrough therapy designation for its AAV2-hAQP1 gene therapy, significantly beating 2025 Q4 revenue expectations, and securing a debt extension agreement with Perceptive.